ARAY
$4.86
Accuray
($.12)
(2.41%)
Earnings Details
1st Quarter September 2021
Wednesday, November 3, 2021 4:05:00 PM
Tweet Share Watch
Summary

Accuray (ARAY) Recent Earnings

Accuray (ARAY) reported a 1st Quarter September 2021 loss of $0.01 per share on revenue of $107.4 million. The consensus estimate was a loss of $0.03 per share on revenue of $88.5 million. Revenue grew 25.9% on a year-over-year basis.

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Results
Reported Earnings
($0.01)
Earnings Whisper
-
Consensus Estimate
($0.03)
Reported Revenue
$107.4 Mil
Revenue Estimate
$88.5 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Accuray Reports Fiscal 2022 First Quarter Financial Results

SUNNYVALE, Calif., Nov. 3, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021.

First Quarter Fiscal 2022 Summary

  • Record net revenue of $107.4 million, including $25.5 million of system revenue in China, as compared to net revenue of $85.3 million in the prior period
  • Gross orders of $70.0 million, an increase of 39 percent from the three months ended September 30, 2020
  • GAAP Net loss of $1.0 million as compared to GAAP Net income of $0.4 million in the prior year. Adjusted EBITDA of $5.4 million as compared to adjusted EBITDA of $9.0 million in the prior year first quarter

Other Recent Operational Highlights 

  • Received 510(k) clearance for VOLO™ Ultra enhancement to the Accuray Precision® treatment planning system for the Radixact® System, full commercial launch at ASTRO 2021
  • Strong demand for ClearRT™ Helical kVCT Imaging for the Radixact® System: 59 global orders received since its commercial release in December 2020
  • New integration with RayStation® treatment planning system for the CyberKnife® M6™ and S7™ Systems, exhibited at ASTRO 2021

"By any measure, our Q1 performance was a very strong start to our FY22 fiscal year. Q1 revenue of $107.4 million represents the largest first fiscal quarter revenue that Accuray has ever recorded. Our performance reflects the visible impact of the investments in innovation we have made to our product portfolio, how those new technologies are being received by customers across the world and a laser-like focus on commercial execution, all of which are driving accelerated revenue growth in our business," said Joshua Levine, Chief Executive Officer.

Q1 Fiscal 2022 Financial Highlights

Total net revenue was $107.4 million for the first quarter of fiscal 2022 compared to $85.3 million for the prior fiscal year first quarter. Product revenue totaled $52.8 million for the first quarter of fiscal 2022 compared to $31.3 million for the prior fiscal year first quarter, while service revenue totaled $54.7 million for the first quarter of fiscal 2022 compared to $54.1 million for the prior fiscal year first quarter.

Total gross profit for the first quarter of fiscal 2022 was $39.5 million or approximately 36.8 percent of total net revenue, comprised of product gross margin of 40.3 percent of product net revenue and service gross margin of 33.4 percent of service net revenue. This compares to total gross profit of $35.4 million or 41.5 percent of total net revenue, comprised of product gross margin of 41.1 percent of product net revenue and service gross margin of 41.7 percent of service net revenue for the prior fiscal year first quarter.

Net loss was $1.0 million, or $0.1 per share, for the first quarter of fiscal 2022, compared to net income of $0.4 million, or an income of $0 per share, for the prior fiscal year first quarter.

Gross product orders totaled $70.0 million for the first quarter of fiscal 2022 compared to $50.5 million for the prior fiscal year first quarter. Order backlog as of September 30, 2021 was $602.9 million, approximately 1 percent higher than at the end of the prior fiscal year first quarter.

Adjusted EBITDA for the first quarter of fiscal 2022 was $5.4 million, compared to $9.0 million for the prior fiscal year first quarter.

Cash, cash equivalents, and short-term restricted cash were $105.2 million as of September 30, 2021, a decrease of $11.7 million from June 30, 2021, primarily due to the payout of employee bonuses earned in the prior fiscal year and a $1 million payment on the company's term loan facility.

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2022 as well as recent corporate developments. Conference call dial-in information is as follows:

  • U.S. callers: (833) 316-0563
  • International callers: (412) 317-5747

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 10161091. An archived webcast will also be available on Accuray's website until Accuray announces its results for the second quarter of fiscal 2022.

Use of Non-GAAP Financial Measures

Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA").  The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results.  A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding total revenue and adjusted EBITDA; expectations regarding the effect of the COVID-19 pandemic on the company and the market in general; expectations regarding the company's commercial strategy and execution as well as long-term growth opportunities; expectations regarding the company's order growth; the company's ability to drive accelerated revenue growth; expectations regarding the company's China joint venture and other partnerships; expectations regarding the company's product innovations and developments; expectations regarding the company's product portfolio and its ability to position the company for growth; the impact of the company's products on its customers and its business, and market adoption of such products, including with respect to the company's VOLO Ultra enhancement and Clear RT Helical kVCT Imaging upgrades as well as other strategic product innovations; expectations regarding the future of radiotherapy treatment and the company's addressable market; and the company's leadership position in radiation oncology innovation and technologies.  These forward-looking statements involve risks and uncertainties.  If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market, the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 17, 2021 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. 

Financial Tables to Follow

 

Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)




Three Months Ended

September 30,




2021



2020


Net revenue:









Products


$

52,759



$

31,258


Services



54,683




54,074


Total net revenue



107,442




85,332


Cost of revenue:









Cost of products



31,509




18,426


Cost of services



36,409




31,503


Total cost of revenue



67,918




49,929


Gross profit



39,524




35,403


Operating expenses:









Research and development



14,382




12,148


Selling and marketing



11,271




8,898


General and administrative



11,460




8,889


Total operating expenses



37,113




29,935


Income from operations



2,411




5,468


Loss on equity investment, net



(340)




(28)


Other expense, net



(2,668)




(4,694)


Income (loss) before provision for income taxes



(597)




746


Provision for income taxes



431




344


Net income (loss)


$

(1,028)



$

402


Net income (loss) per share - basic


$

(0.01)



$

0.00


Net income (loss) per share - diluted


$

(0.01)



$

0.00


Weighted average common shares used in

   computing income (loss) per share:









Basic



90,838




91,194


Diluted



90,838




91,681


 

 

Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)




September 30,



June 30,




2021



2021


Assets









Current assets:









Cash and cash equivalents


$

104,679



$

116,369


Restricted cash



553




560


Accounts receivable, net



94,038




85,360


Inventories



126,493




125,929


Prepaid expenses and other current assets



22,263




21,547


Deferred cost of revenue



2,492




3,008


Total current assets



350,518




352,773


Property and equipment, net



12,263




12,332


Investment in joint venture



14,742




15,935


Goodwill



57,951




57,960


Intangible assets, net



378




435


Operating lease right-of-use assets



21,278




22,522


Other assets



18,646




18,141


Total assets


$

475,776



$

480,098


Liabilities and equity









Current liabilities:









Accounts payable


$

22,569



$

19,467


Accrued compensation



20,848




26,865


Operating lease liabilities, current



8,263




8,169


Other accrued liabilities



31,255




27,471


Customer advances



22,828




24,937


Deferred revenue



78,890




81,660


Short-term debt



3,664




3,790


Total current liabilities



188,317




192,359


Long-term other liabilities



7,835




7,766


Deferred revenue



23,828




23,685


Operating lease liabilities, non-current



15,886




17,441


Long-term debt



194,145




170,007


Total liabilities



430,011




411,258


Equity:









Common stock



91




91


Additional paid-in capital



531,553




554,680


Accumulated other comprehensive income



2,324




2,093


Accumulated deficit



(488,203)




(488,024)


Total equity



45,765




68,840


Total liabilities and equity


$

475,776



$

480,098


 

 

Accuray Incorporated

Summary of Orders and Backlog

(in thousands)

(Unaudited)




Three Months Ended

September 30,




2021



2020


Gross Orders


$

69,984



$

50,528


Net Orders



40,763




23,554


Order Backlog



602,905




597,276


 

 

Accuray Incorporated

Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)




Three Months Ended

September 30,




2021



2020


GAAP net income (loss)


$

(1,028)



$

402


Depreciation and amortization (a)



1,419




1,650


Stock-based compensation



2,516




2,244


Interest expense, net (b)



2,036




4,393


Provision for income taxes



431




344


Adjusted EBITDA


$

5,374



$

9,033









(a) 

consists of depreciation, primarily on property and equipment as well as amortization of intangibles.

(b) 

consists primarily of interest expense associated with outstanding debt.

 

 

Joseph Diaz

Beth Kaplan

Managing Partner, Investor Relations, Lytham Partners, LLC

Public Relations Director, Accuray

+1 (602) 889-9660

+1 (408) 789-4426

jdiaz@accuray.com 

bkaplan@accuray.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2022-first-quarter-financial-results-301415674.html

SOURCE Accuray Incorporated